Labcorp Launches ATN Profile Blood-based Test to Diagnose Alzheimer’s Disease

Labcorp has launched its ATN Profile blood-based test, which combines three well-researched blood biomarkers to identify and assess biological changes associated with Alzheimer’s disease – amyloid plaques, tau tangles and neurodegeneration (ATN) – and may help accelerate the path to diagnosis and intervention.

The test is available through physicians for use with patients who are being evaluated for possible Alzheimer’s disease or other causes of cognitive impairment based on clinical observation and cognitive screenings.

ATN Profile provides physicians with an easily accessible and interpretable blood test to assess pathologies associated with Alzheimer’s disease and other neurodegenerative conditions in appropriate patients, supporting more informed decision-making and improved personalized patient care.

With the release of its ATN Profile, Labcorp is reaffirming its commitment to supporting better care and outcomes for those impacted by Alzheimer’s disease and other neurodegenerative conditions. Labcorp is continuing to invest in studies to demonstrate the impact ATN testing can have in enhancing patient care and the continued development of new drugs to treat and manage the disease, as well as in making other key neurological markers widely accessible to physicians.

To view the source version, please click HERE.


en_GBEnglish (UK)